Investors were bullish on several of L.A.’s publicly traded bioscience companies during the 12 months ending June 30, sending those companies soaring on the Business Journal’s annual public companies list.
Five of the top 10 and seven of the top 15 percentage gainers in share price on the list of 121 publicly traded companies were in the bioscience/pharmaceuticals sector.
All five of those top 10 percentage gainers saw their market capitalization more than double between June 2019 and June 2020.
What’s more, four of the top 10 and six of the top 15 gainers in rank came from the bioscience/pharmaceuticals sector.
This share price surge was in part due to investor enthusiasm for bioscience and pharmaceutical companies nationwide.
“Biotech specifically was the best performing subgroup within health care and in the broader markets for that matter,” said Sahak Manuelian, managing director and head of equities trading for downtown-based brokerage firm Wedbush Securities.
Manuelian said that a national market index of bioscience companies that he tracks showed a 27% gain between June 30, 2019, and June 30, 2020.
Setting the pace
Several of L.A.’s publicly traded companies left that average gain in the dust.
The biggest bioscience percentage gainers for the 12 months ending June 30 were Culver City-based NantKwest Inc. and El Segundo-based NantHealth Inc., the two publicly traded companies in billionaire Patrick Soon-Shiong’s Nantworks family of businesses.
NantKwest’s market cap jumped 1,176% to just under $1.3 billion on June 30 while Nant-Health’s market cap surged 728% to $510 million.
Beverly Hills-based Capricor Therapeutics Inc. saw its share price jump 434% for the year ending June 30. Stock of Temple City-based Fulgent Genetics Inc. surged 206%.
Brentwood-based CytRx Corp., enjoyed a 108% increase in its market cap.
Westlake Village-based MannKind Corp. and Pasadena-based Arrowhead Pharmaceuticals Inc. were also among the major bioscience gainers, each with market cap jumps of about 75%.
Most of these companies exhibited one trait in common over the past 12 months: the ability to shift their focus to the Covid-19 pandemic.
“These companies are taking existing projects they’ve been working on and are pivoting them toward coronavirus applications,” said Ahmed Enany, chief executive of the Southern California Biomedical Council, a downtown-based trade group.
And this agility has caught the attention of investors, who were eager to buy shares of any company showing promise in the fight against Covid-19.
“Biotech innovations are at the core of our fight against current pandemic, where we are particularly seeing a renaissance of a previously overlooked subsector within health care, infectious disease therapeutics and vaccines,” said Mayank Mamtani, senior biotech research analyst and group head of health care research in the San Francisco office of Sawtelle-based B. Riley FBR Inc.
Warp Speed momentum
NantKwest shares spiked in May when that company and ImmunityBio Inc. — another privately held Soon-Shiong business — announced they were participating in Operation Warp Speed, the Trump administration initiative to provide funding for fast-track development of vaccines to combat Covid-19.
Both companies are developing a drug using an altered form of adenovirus (one of the viruses that causes the common cold) to force the body’s immune cells to produce antibodies to fight the coronavirus that causes Covid-19.
Work on this vaccine grew out of the companies’ effort to use an immune system booster to treat cancer. Indeed, an even larger spike of 91% in NantKwest shares occurred in January when the two companies announced that their immunotherapy drug had resulted in successful treatment for pancreatic cancer in a single patient.
Likewise, shares of Capricor Therapeutics surged 253% on April 29 after the company announced positive test results for a drug to treat Covid-19 that it tested on a small group of Covid patients.
That drug has been the company’s lead candidate to treat Duchenne muscular dystrophy, a progressive disorder found primarily in children that causes muscles to become weaker over time. After Covid-19 hit, Capricor quickly pivoted its target research market to that disease.
Genetic testing company Fulgent Genetics also pivoted to combating the pandemic, swiftly developing and distributing two Covid-19 tests and setting to work on a home-based test.
In May, Fulgent’s stock rose 12% when it received emergency use authorization for its Covid-19 tests from the Food & Drug Administration. Then Fulgent secured a key contract as the principal Covid-19 testing lab for the Los Angeles County Department of Public Health.
MannKind, known for its inhalable insulin product Afrezza, partnered with West Los Angeles-based Immix Biopharma Inc. to develop a powder therapy to fight pulmonary infections caused by the coronavirus.
MannKind shares spiked 17% after the announcement. But MannKind’s shares rose even more — 50% in 10 days in mid-June — after a development not related to Covid: The company had announced positive test results for Afrezza at a meeting of the American Diabetes Association.
Arrowhead Pharmaceuticals’ market cap gain was also largely unrelated to Covid-19. Its big share price runup came late last year as investors rushed to the stock after the company reported positive earnings growth.
That growth was largely due to licensing and collaboration agreements inked earlier last year with the Janssen Pharmaceuticals unit of New Brunswick, N.J., pharma giant Johnson & Johnson. Arrowhead did announce in May that it had started a drug development program to address Covid-19 but has offered no further details.
Keep reading the 2020 Largest Public Companies Special Report.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- United Against a Common Foe
- Healthy Returns
- Fulgent Earnings Soar on Covid Testing Surge
- Cryptocurrency, Biotech Set the Pace in a Solid Year for LA Stocks
- Capricor Shares Surge on Test Results for Covid-19 Treatment
- Capricor Shares Surge on Test Results
- Fulgent Revenue Soars on Covid Testing Surge
- Book of Lists Profile: Fulgent Genetics Rises to the Covid Testing Challenge